
Global Therapeutic Peptide Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global Therapeutic Peptide market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Therapeutic Peptide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Therapeutic Peptide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Therapeutic Peptide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Therapeutic Peptide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Therapeutic Peptide include Takeda, Teva, Sanofi, Johnson and Johnson, Novartis, Novo Nordisk, Merck, Eli Lilly and AbbVie, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Therapeutic Peptide, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Therapeutic Peptide, also provides the sales of main regions and countries. Of the upcoming market potential for Therapeutic Peptide, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Therapeutic Peptide sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Therapeutic Peptide market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Therapeutic Peptide sales, projected growth trends, production technology, application and end-user industry.
Therapeutic Peptide Segment by Company
Takeda
Teva
Sanofi
Johnson and Johnson
Novartis
Novo Nordisk
Merck
Eli Lilly
AbbVie
AstraZeneca
Ipsen
Therapeutic Peptide Segment by Type
Oral
Injection
Other
Therapeutic Peptide Segment by Application
Central Nervous System
Metabolic Disorders
Cancer
Other
Therapeutic Peptide Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Peptide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Peptide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Peptide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Therapeutic Peptide market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Therapeutic Peptide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Therapeutic Peptide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Therapeutic Peptide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
According to APO Research, The global Therapeutic Peptide market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Therapeutic Peptide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Therapeutic Peptide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Therapeutic Peptide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Therapeutic Peptide is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Therapeutic Peptide include Takeda, Teva, Sanofi, Johnson and Johnson, Novartis, Novo Nordisk, Merck, Eli Lilly and AbbVie, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Therapeutic Peptide, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Therapeutic Peptide, also provides the sales of main regions and countries. Of the upcoming market potential for Therapeutic Peptide, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Therapeutic Peptide sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Therapeutic Peptide market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Therapeutic Peptide sales, projected growth trends, production technology, application and end-user industry.
Therapeutic Peptide Segment by Company
Takeda
Teva
Sanofi
Johnson and Johnson
Novartis
Novo Nordisk
Merck
Eli Lilly
AbbVie
AstraZeneca
Ipsen
Therapeutic Peptide Segment by Type
Oral
Injection
Other
Therapeutic Peptide Segment by Application
Central Nervous System
Metabolic Disorders
Cancer
Other
Therapeutic Peptide Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Peptide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Peptide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Peptide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Therapeutic Peptide market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Therapeutic Peptide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Therapeutic Peptide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Therapeutic Peptide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Table of Contents
197 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Therapeutic Peptide Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Therapeutic Peptide Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global Therapeutic Peptide Sales Estimates and Forecasts (2020-2031)
- 1.5 Global Therapeutic Peptide Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global Therapeutic Peptide Market Dynamics
- 2.1 Therapeutic Peptide Industry Trends
- 2.2 Therapeutic Peptide Industry Drivers
- 2.3 Therapeutic Peptide Industry Opportunities and Challenges
- 2.4 Therapeutic Peptide Industry Restraints
- 3 Therapeutic Peptide Market by Manufacturers
- 3.1 Global Therapeutic Peptide Revenue by Manufacturers (2020-2025)
- 3.2 Global Therapeutic Peptide Sales by Manufacturers (2020-2025)
- 3.3 Global Therapeutic Peptide Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global Therapeutic Peptide Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Therapeutic Peptide Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Therapeutic Peptide Manufacturers, Product Type & Application
- 3.7 Global Therapeutic Peptide Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Therapeutic Peptide Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Therapeutic Peptide Players Market Share by Revenue in 2024
- 3.8.3 2024 Therapeutic Peptide Tier 1, Tier 2, and Tier 3
- 4 Therapeutic Peptide Market by Type
- 4.1 Therapeutic Peptide Type Introduction
- 4.1.1 Oral
- 4.1.2 Injection
- 4.1.3 Other
- 4.2 Global Therapeutic Peptide Sales by Type
- 4.2.1 Global Therapeutic Peptide Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Therapeutic Peptide Sales by Type (2020-2031)
- 4.2.3 Global Therapeutic Peptide Sales Market Share by Type (2020-2031)
- 4.3 Global Therapeutic Peptide Revenue by Type
- 4.3.1 Global Therapeutic Peptide Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Therapeutic Peptide Revenue by Type (2020-2031)
- 4.3.3 Global Therapeutic Peptide Revenue Market Share by Type (2020-2031)
- 5 Therapeutic Peptide Market by Application
- 5.1 Therapeutic Peptide Application Introduction
- 5.1.1 Central Nervous System
- 5.1.2 Metabolic Disorders
- 5.1.3 Cancer
- 5.1.4 Other
- 5.2 Global Therapeutic Peptide Sales by Application
- 5.2.1 Global Therapeutic Peptide Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Therapeutic Peptide Sales by Application (2020-2031)
- 5.2.3 Global Therapeutic Peptide Sales Market Share by Application (2020-2031)
- 5.3 Global Therapeutic Peptide Revenue by Application
- 5.3.1 Global Therapeutic Peptide Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Therapeutic Peptide Revenue by Application (2020-2031)
- 5.3.3 Global Therapeutic Peptide Revenue Market Share by Application (2020-2031)
- 6 Global Therapeutic Peptide Sales by Region
- 6.1 Global Therapeutic Peptide Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Therapeutic Peptide Sales by Region (2020-2031)
- 6.2.1 Global Therapeutic Peptide Sales by Region (2020-2025)
- 6.2.2 Global Therapeutic Peptide Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America Therapeutic Peptide Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America Therapeutic Peptide Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Therapeutic Peptide Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe Therapeutic Peptide Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Therapeutic Peptide Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific Therapeutic Peptide Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Therapeutic Peptide Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa Therapeutic Peptide Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global Therapeutic Peptide Revenue by Region
- 7.1 Global Therapeutic Peptide Revenue by Region
- 7.1.1 Global Therapeutic Peptide Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global Therapeutic Peptide Revenue by Region (2020-2025)
- 7.1.3 Global Therapeutic Peptide Revenue by Region (2026-2031)
- 7.1.4 Global Therapeutic Peptide Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America Therapeutic Peptide Revenue (2020-2031)
- 7.2.2 North America Therapeutic Peptide Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe Therapeutic Peptide Revenue (2020-2031)
- 7.3.2 Europe Therapeutic Peptide Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Therapeutic Peptide Revenue (2020-2031)
- 7.4.2 Asia-Pacific Therapeutic Peptide Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Therapeutic Peptide Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa Therapeutic Peptide Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 Takeda
- 8.1.1 Takeda Comapny Information
- 8.1.2 Takeda Business Overview
- 8.1.3 Takeda Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 Takeda Therapeutic Peptide Product Portfolio
- 8.1.5 Takeda Recent Developments
- 8.2 Teva
- 8.2.1 Teva Comapny Information
- 8.2.2 Teva Business Overview
- 8.2.3 Teva Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 Teva Therapeutic Peptide Product Portfolio
- 8.2.5 Teva Recent Developments
- 8.3 Sanofi
- 8.3.1 Sanofi Comapny Information
- 8.3.2 Sanofi Business Overview
- 8.3.3 Sanofi Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 Sanofi Therapeutic Peptide Product Portfolio
- 8.3.5 Sanofi Recent Developments
- 8.4 Johnson and Johnson
- 8.4.1 Johnson and Johnson Comapny Information
- 8.4.2 Johnson and Johnson Business Overview
- 8.4.3 Johnson and Johnson Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 Johnson and Johnson Therapeutic Peptide Product Portfolio
- 8.4.5 Johnson and Johnson Recent Developments
- 8.5 Novartis
- 8.5.1 Novartis Comapny Information
- 8.5.2 Novartis Business Overview
- 8.5.3 Novartis Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.5.4 Novartis Therapeutic Peptide Product Portfolio
- 8.5.5 Novartis Recent Developments
- 8.6 Novo Nordisk
- 8.6.1 Novo Nordisk Comapny Information
- 8.6.2 Novo Nordisk Business Overview
- 8.6.3 Novo Nordisk Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.6.4 Novo Nordisk Therapeutic Peptide Product Portfolio
- 8.6.5 Novo Nordisk Recent Developments
- 8.7 Merck
- 8.7.1 Merck Comapny Information
- 8.7.2 Merck Business Overview
- 8.7.3 Merck Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.7.4 Merck Therapeutic Peptide Product Portfolio
- 8.7.5 Merck Recent Developments
- 8.8 Eli Lilly
- 8.8.1 Eli Lilly Comapny Information
- 8.8.2 Eli Lilly Business Overview
- 8.8.3 Eli Lilly Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.8.4 Eli Lilly Therapeutic Peptide Product Portfolio
- 8.8.5 Eli Lilly Recent Developments
- 8.9 AbbVie
- 8.9.1 AbbVie Comapny Information
- 8.9.2 AbbVie Business Overview
- 8.9.3 AbbVie Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.9.4 AbbVie Therapeutic Peptide Product Portfolio
- 8.9.5 AbbVie Recent Developments
- 8.10 AstraZeneca
- 8.10.1 AstraZeneca Comapny Information
- 8.10.2 AstraZeneca Business Overview
- 8.10.3 AstraZeneca Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.10.4 AstraZeneca Therapeutic Peptide Product Portfolio
- 8.10.5 AstraZeneca Recent Developments
- 8.11 Ipsen
- 8.11.1 Ipsen Comapny Information
- 8.11.2 Ipsen Business Overview
- 8.11.3 Ipsen Therapeutic Peptide Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.11.4 Ipsen Therapeutic Peptide Product Portfolio
- 8.11.5 Ipsen Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Therapeutic Peptide Value Chain Analysis
- 9.1.1 Therapeutic Peptide Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Therapeutic Peptide Production Mode & Process
- 9.2 Therapeutic Peptide Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Therapeutic Peptide Distributors
- 9.2.3 Therapeutic Peptide Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.